Opioid claimants to lose $1bn as Mallinckrodt’s Ch11 plan confirmed

Opioid claimants to lose $1bn as Mallinckrodt’s Ch11 plan confirmed

Ireland-registered pharma group Mallinckrodt has secured court approval of its second Chapter 11 plan in two years, leaving its opioid creditors with US$1 billion less than the company agreed to pay them under its first plan last year.

Unlock unlimited access to all Global Restructuring Review content